NCT00578604

Brief Summary

The objective of this project is to further the development of a non-invasive optically based NIR (Near Infrared) device to enable the quantitative diagnosis, monitoring and treatment optimization of chronic wounds (especially diabetic) in a clinical setting. The end goal of this project is a portable and compact device that would be simple to operate by minimally trained health care personnel. Our animal studies have shown that the early healing of chronic wounds can be characterized by absorption and scattering of light at near infrared wavelengths ranging from 680 nm to 950 nm. If our project is successful we will be providing the clinician the ability to predict if a wound is healing and if a particular treatment is successful in accelerating healing before any changes are observed by wound size contraction or other visible clinical signs. Our hope is that the fNIR optical device will provide conclusive therapeutic treatment information as early as 5 weeks after initial evaluation, before it would be obvious on gross examination of the patient.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2007

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2007

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

December 20, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 21, 2007

Completed
6.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

March 30, 2017

Status Verified

March 1, 2017

Enrollment Period

6.8 years

First QC Date

December 20, 2007

Last Update Submit

March 28, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • diffuse near infrared spectroscopy measurements

    The end goal of this project is a portable and compact device that would be simple to operate by minimally trained health care personnel and is comparable to SOC doppler.

    3 years

Study Arms (2)

Patients with a diabetic wound

Patients with a diabetic wound

Device: diffuse near infrared spectroscopy measurements

Control

Patients without a diabetic wound

Device: diffuse near infrared spectroscopy measurements

Interventions

Measure blood flow to diabetic wounds

ControlPatients with a diabetic wound

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Recruited patients will be patients with diabetes who have chronic wounds and will likely have other co-morbidities associated with chronic diabetes. Control subjects do not have diabetes and do not have wounds.

You may qualify if:

  • Subjects must be 18-65 years of age
  • Subjects must have no history of diabetes
  • Subjects must have no history of vascular disease
  • Subjects must have no findings of vascular disease on physical examination
  • Subjects who are not allergic to Tegaderm
  • Subjects must be 18-65 years of age
  • Subjects must have documented diabetes mellitus for at least 6 months.
  • Subjects must have at least one documented chronic wound for a minimum 8 weeks.
  • A chronic wound is defined as any wound that has not healed after 8 weeks and has a minimum surface area of 1cm2. There is no maximum wound size.
  • Wound(s) must be secondary to the complications of diabetes, including vascular disease neuropathy, or both.
  • Wounds must be on the ankles or feet
  • Subjects who are not allergic to Tegaderm

You may not qualify if:

  • Subject must not be \<18 or \>65 years of age
  • Subjects with major infections, abscesses, or untreated osteomyelitis will be excluded until appropriately treated.
  • Subjects will not be excluded based upon the existence of other co-morbidities associated with chronic diabetes, including retinopathy, nephropathy, peripheral neuropathy, or cardiovascular disease except as follows:
  • Subjects who have moderate to severe vascular insufficiency (defined as ankle brachial index \<0.75 or toe-brachial index \<0.5)
  • Subjects who are unable to return for weekly follow-up appointments will not be included.
  • Pregnant or lactating people will not be invited to participate.
  • Subjects who are allergic to Tegaderm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Drexel University College of Medicine Wound Care Center

Philadelphia, Pennsylvania, 19102, United States

Location

MeSH Terms

Conditions

Diabetic Foot

Condition Hierarchy (Ancestors)

Diabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesDiabetic Neuropathies

Study Officials

  • Michael S Weingarten, M.D.

    Drexel University College of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 20, 2007

First Posted

December 21, 2007

Study Start

September 1, 2007

Primary Completion

June 1, 2014

Study Completion

June 1, 2014

Last Updated

March 30, 2017

Record last verified: 2017-03

Locations